Αρχική World News Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid... World News Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Από Ogkologos - 17 Φεβρουαρίου, 2026 407 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ AI for early cancer detection: where are we now? Could virtual reality become a reality in cancer supportive care? EMA recommends granting a marketing authorisation for daraxonrasib MOST POPULAR ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers 10 Νοεμβρίου, 2022 EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan 13 Ιουλίου, 2023 EMA Recommends Granting a Marketing Authorisation for Generic Dasatinib 10 Φεβρουαρίου, 2022 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... 6 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome Dog Finds Woman’s Lost Wedding Ring At The Beach What if we count all that still remains? No OS Benefit for Active Maintenance Treatment with Olaparib Relative to...